Virtual Health Group Project 2011/12
|Laura Oxley||07989361623||L dot J dot Oxley at warwick dot ac dot uk|
|Tom Ridings||07876350563||T dot Ridings at warwick dot ac dot uk|
|Domonic Hoyte||07974110068||D dot Hoyte at warwick dot ac dot uk|
|Charlie Johnson||07816128574||Charles dot Johnson at warwick dot ac dot uk|
|Daniel Dhillon||07525218445||Daniel dot Dhillon at warwick dot ac dot uk|
|Adrian Thomas||07538370933||Adrian dot Thomas at warwick dot ac dot uk|
The airways diseases asthma and chronic obstructive pulmonary disease affect over 400 million people world-wide and cause considerable morbidity and mortality. Airways disease costs the European Union in excess of 56 billion per annum. Current therapies are inadequate and we do not have sufficient tools to predict disease progression or response to current or future therapies. Our consortium, Airway Disease PRedicting Outcomes through Patient Specific Computational Modelling (AirPROM), brings together the existing clinical consortia (EvA FP7, U-BIOPRED IMI and BTS Severe Asthma), and expertise in physiology, radiology, image analysis, bioengineering, data harmonization, data security and ethics, computational modelling and systems biology. We shall develop an integrated multi-scale model building upon existing models.
This airway model will be comprised of an integrated micro-scale and macro-scale airway model informed and validated by omic data and ex vivo models at the genome-transcriptome-cell-tissue scale and by CT and functional MRI imaging coupled to detailed physiology at the tissue-organ scale utilising Europe's largest airway disease cohort. Validation will be undertaken cross-sectionally, following interventions and after longitudinal follow-up to incorporate both spatial and temporal dimensions.